…
At an immuno-oncology meeting in New York — where on Monday [Oct. 1] afternoon Allison was greeted like a rock star, with scientists asking for his autograph and requesting selfies — three experts in cancer immunotherapy said they were “shocked” that [other] scientists who were key to the development of checkpoint inhibitors that exploit the PD-1 pathway were overlooked.
…
The 2018 medicine Nobel is only the latest where the rule of three gives a misleading impression of how science is done. Because it perpetuates the lone genius myth, said Venkatraman Ramakrishnan of Britain’s Medical Research Council, a winner of the 2009 Nobel Prize in chemistry and president of the Royal Society, “the rule of three is inappropriate to 21st-century science.”
Read full, original post: The snub club: Crucial contributors to cancer immunotherapy were excluded from the medicine Nobel